305 related articles for article (PubMed ID: 27741368)
21. Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
Christie EL; Fereday S; Doig K; Pattnaik S; Dawson SJ; Bowtell DDL
J Clin Oncol; 2017 Apr; 35(12):1274-1280. PubMed ID: 28414925
[TBL] [Abstract][Full Text] [Related]
22. Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next-generation sequencing.
Lee JY; Yoon JK; Kim B; Kim S; Kim MA; Lim H; Bang D; Song YS
BMC Cancer; 2015 Feb; 15():85. PubMed ID: 25881093
[TBL] [Abstract][Full Text] [Related]
23. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract][Full Text] [Related]
24. Mutational heterogeneity in non-serous ovarian cancers.
Teer JK; Yoder S; Gjyshi A; Nicosia SV; Zhang C; Monteiro ANA
Sci Rep; 2017 Aug; 7(1):9728. PubMed ID: 28852190
[TBL] [Abstract][Full Text] [Related]
25. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
26. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
27. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
28. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
[TBL] [Abstract][Full Text] [Related]
29. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas.
Kuo KT; Guan B; Feng Y; Mao TL; Chen X; Jinawath N; Wang Y; Kurman RJ; Shih IeM; Wang TL
Cancer Res; 2009 May; 69(9):4036-42. PubMed ID: 19383911
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
31. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.
McIntyre JB; Rambau PF; Chan A; Yap S; Morris D; Nelson GS; Köbel M
Histopathology; 2017 Feb; 70(3):347-358. PubMed ID: 27575406
[TBL] [Abstract][Full Text] [Related]
32. Nuclear-mitochondrial genomic profiling reveals a pattern of evolution in epithelial ovarian tumor stem cells.
Wani AA; Sharma N; Shouche YS; Bapat SA
Oncogene; 2006 Oct; 25(47):6336-44. PubMed ID: 16732329
[TBL] [Abstract][Full Text] [Related]
33. K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.
Diebold J; Seemüller F; Löhrs U
Lab Invest; 2003 Feb; 83(2):251-8. PubMed ID: 12594239
[TBL] [Abstract][Full Text] [Related]
34. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
[TBL] [Abstract][Full Text] [Related]
35. Critical molecular abnormalities in high-grade serous carcinoma of the ovary.
Köbel M; Huntsman D; Gilks CB
Expert Rev Mol Med; 2008 Aug; 10():e22. PubMed ID: 18671886
[TBL] [Abstract][Full Text] [Related]
36. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
37. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data.
Vang R; Shih IeM; Salani R; Sugar E; Ayhan A; Kurman RJ
Am J Surg Pathol; 2008 Nov; 32(11):1667-74. PubMed ID: 18769340
[TBL] [Abstract][Full Text] [Related]
38. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
39. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
[TBL] [Abstract][Full Text] [Related]
40. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]